I am a
Home I AM A Search Login

Papers of the Week

2020 08

J Invest Dermatol



A Phase II, Open Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.


Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G, Hernandez L, Kaffenberger J, Guido G, Lucas K, Montes D, Gold M, Babcock C, Simard J
J Invest Dermatol. 2020 08; 140(8):1538-1545.e2.
PMID: 32004568.


To evaluate the safety and efficacy of bermekimab, an interleukin-1⍺ inhibitor, in the treatment of hidradenitis suppurativa (HS).